PsychoGenics Announces Positive Phase-IIa For Its First-in-Class Partial 5-HT1A - 5-HT1B Receptor Agonist In ADHD

PsychoGenics Inc. announced positive data from its randomized, placebo controlled, multicenter, Phase IIa trial of eltoprazine, the company's lead partial 5-HT1A - 5-HT1B receptor agonist, in adult patients with Attention Deficit/ Hyperactivity Disorder (ADHD). ...

Write comment to this article:

Subject:

Name:

email or site:

Code: